Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -15.78M | -15.78M | -15.78M | -2.37M | -5.83M |
| Gross Profit | 15.78M | 15.78M | 15.78M | 2.37M | 5.83M |
| SG&A Expenses | 27.42M | 25.68M | 23.56M | 22.52M | 18.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.26M | 47.70M | 45.25M | 52.44M | 45.01M |
| Operating Income | -58.26M | -47.70M | -45.25M | -52.44M | -45.01M |
| Income Before Tax | -60.64M | -50.96M | -48.26M | -47.66M | -41.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.64 | -50.96 | -48.26 | -47.66 | -41.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.64M | -50.96M | -48.26M | -47.66M | -41.50M |
| EBIT | -58.26M | -47.70M | -45.25M | -52.44M | -45.01M |
| EBITDA | -58.21M | -47.64M | -45.19M | -52.38M | -44.96M |
| EPS Basic | -0.44 | -0.44 | -0.50 | -0.56 | -1.08 |
| Normalized Basic EPS | -0.24 | -0.24 | -0.28 | -0.36 | -0.68 |
| EPS Diluted | -0.44 | -0.44 | -0.50 | -0.56 | -1.08 |
| Normalized Diluted EPS | -0.24 | -0.24 | -0.28 | -0.36 | -0.68 |
| Average Basic Shares Outstanding | 560.57M | 476.00M | 393.24M | 341.67M | 260.50M |
| Average Diluted Shares Outstanding | 560.57M | 476.00M | 393.24M | 341.67M | 260.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |